Seres Therapeutics (NASDAQ:MCRB) Lowered to “Sell” Rating by StockNews.com

StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note published on Saturday morning.

Other analysts have also recently issued research reports about the company. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lowered Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Down 0.7 %

Shares of MCRB opened at $0.84 on Friday. The firm has a market cap of $144.15 million, a price-to-earnings ratio of -3.67 and a beta of 2.13. The company’s fifty day moving average is $0.83 and its 200-day moving average is $0.91. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.53.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Seres Therapeutics by 42.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 222,771 shares during the period. Geode Capital Management LLC boosted its holdings in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the period. FMR LLC grew its position in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares during the last quarter. State Street Corp increased its holdings in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares during the period. Finally, Providence Wealth Advisors LLC raised its position in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the last quarter. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.